A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a sma

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a sma

Item

http://www.wikidata.org/entity/Q36984261

Q36984261

about

Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders Current best practice in the management of hypertensive disorders in pregnancy Pre-eclampsia: its pathogenesis and pathophysiolgy The imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsia Angiogenic factors in preeclampsia: potential for diagnosis and treatment A brief overview of preeclampsia Is inflammation the cause of pre-eclampsia?Angiogenic factors in diagnosis, management, and research in preeclampsia.Effect of Low Molecular Weight Heparins (LMWHs) on antiphospholipid Antibodies (aPL)-mediated inhibition of endometrial angiogenesis DBA-lectin reactivity defines mouse uterine natural killer cell subsets with biased gene expression Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.Effects of hypoxia-inducible factor-1alpha overexpression in pregnant mice: possible implications for preeclampsia and intrauterine growth restriction Is there an association between platelet count during the first trimester and preeclampsia or other obstetric complications later in pregnancy?Pre-eclampsia part 1: current understanding of its pathophysiology.Do anti-angiogenic or angiogenic factors contribute to the protection of birth weight at high altitude afforded by Andean ancestry?Increased protein-coding mutations in the mitochondrial genome of African American women with preeclampsia.Expression of placental growth factor mRNA in preeclampsia.The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age.Epistasis between COMT and MTHFR in maternal-fetal dyads increases risk for preeclampsia.Maternal and fetoplacental hypoxia do not alter circulating angiogenic growth effectors during human pregnancy.Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.Defining normal and abnormal fetal growth: promises and challenges.Maternal plasma soluble TRAIL is decreased in preeclampsia.Endothelial Dysfunction in Severe Preeclampsia is Mediated by Soluble Factors, Rather than Extracellular Vesicles.Can changes in angiogenic biomarkers between the first and second trimesters of pregnancy predict development of pre-eclampsia in a low-risk nulliparous patient population?New developments in the pathogenesis of preeclampsia Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation Circulating soluble endoglin levels in pregnant women in Cameroon and Malawi--associations with placental malaria and fetal growth restriction.Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery.Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study.Endoglin in amniotic fluid as a risk factor for the subsequent development of bronchopulmonary dysplasia.The anti-aging factor α-klotho during human pregnancy and its expression in pregnancies complicated by small-for-gestational-age neonates and/or preeclampsia.Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations.Prediction of preeclampsia and induced delivery at <34 weeks gestation by sFLT-1 and PlGF in patients with abnormal midtrimester uterine Doppler velocimetry: a prospective cohort analysis.Microbial invasion of the amniotic cavity in pregnancies with small-for-gestational-age fetuses.Retinol binding protein 4--a novel association with early-onset preeclampsia.Sera from preeclampsia patients elicit symptoms of human disease in mice and provide a basis for an in vitro predictive assay The vascular endothelial growth factor family in adverse pregnancy outcomes.Evolutionary origins of the placental expression of chromosome 19 cluster galectins and their complex dysregulation in preeclampsia.Unexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluid

P2860

Q21144276-218F06FA-77CA-444D-B7B5-1C25ED276E03 Q26739585-2572F0B3-8B9E-4E3D-9D6B-EB64958A09E8 Q26746841-307B6227-9D0F-42D2-A218-68AFB93462C1 Q26798193-166F5023-5BF7-43C3-8285-AB4FF1BBCD44 Q26825774-D3641B25-7566-4A7D-BEE7-519C0AEE96F6 Q27003730-45AC8194-1C2D-4BE4-9F1E-C743F397B7F8 Q27007059-221173A2-E000-498A-B59F-812A8207B1AE Q27692060-7990E102-0A73-4738-9D78-16ED36239D99 Q28740531-D7E7D158-0C2A-47A0-ABAE-A341FA601006 Q30525576-0DEFCBCF-6DF8-490C-AB37-85D62C517333 Q30990384-3106EA53-C514-44D0-BF18-5C1267453214 Q33392329-C0013B29-0332-4403-9577-5352EE994E83 Q33405779-218C34E8-48AA-4232-AB54-6548294FBF63 Q33416340-1B601EA2-03E1-4069-B839-2741B9B6B743 Q33624964-A49B5EEF-557D-4CAB-8082-0245FA8DBAF6 Q33714774-CDA1D475-DE10-4579-8E83-C8A8574316A5 Q33736940-9E8C266F-7311-4472-AE4E-76F8A65B0FCB Q33755648-7B992F97-683D-4BC6-9E13-48D0D3F307F8 Q33815618-FACE47F2-A4E1-4284-8D8C-09C9891FCBAF Q33826353-F66F60EA-A177-4427-B3E8-25DA60F7DB35 Q33863973-CB275898-A63A-4CE0-8E38-9168EA5F9C98 Q33886558-F713B999-6DEE-463A-83C9-B1AF482A39BF Q33909572-99E4A9B0-ECEF-4DE7-9E8F-09A988C04181 Q33918999-2ACC9B27-7F51-4DEC-A2AF-BADDD6F58AE5 Q33923716-0D8E8549-EF79-4CD0-9FE0-A48C46DB6C17 Q33935675-8C95F930-275B-4A51-84FE-8BE0A4E096C1 Q33940112-A8E61FD8-025C-4DBA-9538-D378EE733B38 Q34037890-E6CB138F-5B15-41EC-BE12-8A9E280B00D6 Q34116772-8BDA503A-49E9-46FD-B85B-70E8893BCF4B Q34119026-A2C8FEE1-0977-44B9-842D-BBA867F4DB7C Q34119241-EE782F84-704F-4022-A368-FDB1E1439E8F Q34150192-38751885-F828-4520-ADB6-C03D209ED86D Q34151967-D105D045-6B6D-4764-8839-E63E61B3D04C Q34174363-D9587A67-6DBA-463E-A967-0A31125A625C Q34234655-88166A53-F31F-4C28-A97C-BD248F5F0D02 Q34234671-5935B1EF-2A4A-4302-8AD8-3D5CA14EFD91 Q34254466-50326934-D09A-4129-B756-D792C5C2D3D4 Q34267491-7C6A9121-8956-4918-AB88-4323C21679CE Q34372600-82371893-D5CF-4D2B-9287-B366E3E157BA Q34470845-850BD678-BAEB-47BB-B1CB-113192AB7AE8

P2860

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a sma

Item

http://www.wikidata.org/entity/Q36984261

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

A longitudinal study of angiog ...... preeclampsia and deliver a sma

@en

type

Item

label

A longitudinal study of angiog ...... preeclampsia and deliver a sma

@en

prefLabel

A longitudinal study of angiog ...... preeclampsia and deliver a sma

@en

P1476

A longitudinal study of angiog ...... preeclampsia and deliver a sma

@en

P2093

David Todem

http://www.w3.org/2001/XMLSchema#string

Francesca Gotsch

http://www.w3.org/2001/XMLSchema#string

Hwan Chung

http://www.w3.org/2001/XMLSchema#string

Jimmy Espinoza

http://www.w3.org/2001/XMLSchema#string

Juan Pedro Kusanovic

http://www.w3.org/2001/XMLSchema#string

Jyh Kae Nien

http://www.w3.org/2001/XMLSchema#string

Offer Erez

http://www.w3.org/2001/XMLSchema#string

Richard J Levine

http://www.w3.org/2001/XMLSchema#string

Roberto Romero

http://www.w3.org/2001/XMLSchema#string

Sam Edwin

http://www.w3.org/2001/XMLSchema#string

P2860

Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily

Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies

Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1

Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen

Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells

The biology of VEGF and its receptors

Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts

Soluble endoglin contributes to the pathogenesis of preeclampsia

Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders

Vascular-specific growth factors and blood vessel formation

P304

9-23

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14767050701830480

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ricardo Gomez

Tinnakorn Chaiworapongsa

S Ananth Karumanchi

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5675292

http://www.w3.org/2001/XMLSchema#string

P698

18175241

http://www.w3.org/2001/XMLSchema#string

P921

endothelium

pre-eclampsia

P932

2587364

http://www.w3.org/2001/XMLSchema#string

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a sma

about

P2860

P2860

A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a sma

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932